Phaseline

Targets › MAPK8IP3

MAPK8IP3 (C-Jun-amino-terminal kinase-interacting protein 3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Feb 2027.

The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity). (UniProt, Q9UPT6)

Open in Phaseline: the race on MAPK8IP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
n-Lorem FoundationnL-MAPK8-001
Antisense oligonucleotide targeting MAPK8IP3
MAPK8IP3Phase 1Neurodevelopmental Disorder With or Without Variable Brain AbnormalitiesFeb 2027

Conditions

Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (1)

Modalities

small molecule (1)

Companies

n-Lorem Foundation (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.